During the past decade, Istituto Regina Elena; Oncologia Medica A conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 13 clinical trials were completed, i.e. on average, 108.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto Regina Elena; Oncologia Medica A" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Consorzio Oncotech" with 2 trials sponsored, "Gruppo Oncologico Italiano di Ricerca Clinica" with 1 trials sponsored, "Pfizer" with 1 trials sponsored and "Puma Biotechnology, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Regina Elena; Oncologia Medica A" #1 collaborator was "AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology" with 2 trials as a collaborator, "AOU S. Orsola Malpighi - Clinical Trial Office" with 1 trials as a collaborator, "Bioikos Ambiente Srl" with 1 trials as a collaborator, "Clinical Research Technology S.r.l." with 1 trials as a collaborator and "Ipsen" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Istituto Regina Elena; Oncologia Medica A" are "Breast Cancer" (3 trials), "Metastatic Breast Cancer" (2 trials), "Non-Small Cell Lung Cancer" (2 trials), "Ovarian Cancer" (2 trials) and "Advanced BRAFV600 Wild-type Melanoma" (1 trials). Many other conditions were trialed in "Istituto Regina Elena; Oncologia Medica A" in a lesser frequency.

Most popular intervention types in "Istituto Regina Elena; Oncologia Medica A" are "Drug" (22 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (6 trials), "Bevacizumab" (3 trials), "Cobimetinib" (3 trials), "Pertuzumab" (3 trials) and "Vemurafenib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Regina Elena; Oncologia Medica A" are 17 trials for "All" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Istituto Regina Elena; Oncologia Medica A". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Istituto Regina Elena; Oncologia Medica A, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Regina Elena; Oncologia Medica A, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".